Wave Life Sciences announced positive interim data from the Phase 1 INLIGHT trial of WVE-007, showing improvements in body composition with fat loss and lean mass increase at three months.
The trial demonstrated a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass after a single subcutaneous 240 mg dose of WVE-007.
Results support potential once or twice-yearly dosing of WVE-007 with a favorable safety profile and robust suppression of serum Activin E.
Positive Body Composition Changes
WVE-007 showed reductions in visceral and total body fat, along with an increase in lean mass after a single dose.
Support for Once or Twice-Yearly Dosing
The sustained suppression of serum Activin E indicates potential for less frequent dosing schedules.
Therapeutic Potential for Obesity
WVE-007 has the potential to provide a meaningful treatment for individuals with obesity, offering multiple dosing options.
Future Phase 2 Trials
Planned Phase 2 trials will evaluate WVE-007 as both a monotherapy and an add-on therapy in populations with higher BMI and related co-morbidities.
- The results of the INLIGHT trial suggest that WVE-007 has the potential to transform the obesity treatment paradigm by addressing key limitations of existing treatments like GLP-1s.
- The observed fat loss without muscle loss and favorable safety profile point towards a promising therapeutic option for over one billion individuals living with obesity.
Wave Life Sciences' positive interim data from the Phase 1 INLIGHT trial of WVE-007 indicate significant potential for addressing obesity with improved body composition and favorable safety profiles. The results support further development and evaluation of WVE-007 in Phase 2 trials for different dosing strategies and patient populations.